Pharmacological inhibition of sEH attenuated diabetes-induced mitochondrial damage, mitochondrial reactive oxygen species (mtROS) production, NLRP3 inflammasome activation, and renal dysfunction both <i>in vivo</i> and <i>in vitro</i>. This evidence concerns the gene NLRP3 and diabetes mellitus.